ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES VOTES TO RECOMMEND ROUTINE USE OF PFIZER?S PREVNAR 20? (PNEUMOCOCCAL 20-VALENT CONJUGATE VACCINE) IN ADULTS
Pfizer Inc. (NYSE:PFE) announced today that the Centers for Disease Control and Prevention?s (CDC) Advisory Committee on Immunization Practices (ACIP) voted to recommend PREVNAR 20??(Pneumococcal 20-valent Conjugate Vaccine) for routine use to help protect adults against invasive disease and pneumonia caused by the 20?Streptococcus pneumoniae?(pneumococcus) serotypes in the vaccine. Specifically, the ACIP voted to recommend the following:
- Adults 65 years of age or older who have not previously received a pneumococcal conjugate vaccine or whose previous vaccination history is unknown should receive a pneumococcal conjugate vaccine (either PCV20 or PCV15). If PCV15 is used, this should be followed by a dose of PPSV23.
- Adults aged 19 years of age or older with certain underlying medical conditions or other risk factors1?who have not previously received a pneumococcal conjugate vaccine or whose previous vaccination history is unknown should receive a pneumococcal conjugate vaccine (either PCV20 or PCV15). If PCV15 is used, this should be followed by a dose of PPSV23.
- PREVNAR 20??is a vaccine indicated for active immunization for the prevention of pneumonia and invasive disease caused by?Streptococcus pneumoniae?serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F in adults 18 years of age and older
- This indication for the prevention of pneumonia caused by?S. pneumoniae?serotypes 8, 10A, 11A, 12F, 15B, 22F, and 33F is approved under accelerated approval based on immune responses as measured by opsonophagocytic activity (OPA) assay. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
- PREVNAR 20??should not be given to anyone with a history of severe allergic reaction to any component of PREVNAR 20??or any diphtheria toxoid?containing vaccine
- Some adults with weakened immune systems may have a lower response to PREVNAR 20?. Safety data are not available for these groups. Your healthcare provider can tell you if PREVNAR 20??is right for you
- In adults 18 years of age and older, the most common side effects were pain at the injection site, muscle pain, fatigue, and headache
- Ask your healthcare provider about the risks and benefits of PREVNAR 20?. Only a healthcare provider can decide if PREVNAR 20??is right for you
View source version on?businesswire.com:?https://www.businesswire.com/news/home/20211020006069/en/
Media Contact: PfizerMediaRelations@Pfizer.com? +1 (212) 733-1226 Investor Contact: IR@Pfizer.com? +1 (212) 733-4848 Source: Pfizer Inc.